4.6 Review

Animal Models of Parkinson's Disease: Limits and Relevance to Neuroprotection Studies

期刊

MOVEMENT DISORDERS
卷 28, 期 1, 页码 61-70

出版社

WILEY
DOI: 10.1002/mds.25108

关键词

6-OHDA; MPTP; alpha-synuclein; LRRK2; neurodegeneration; dopamine; viral vectors

资金

  1. Agence Nationale de la Recherche [ANR-07-JCJC-0090, ANR-08-MNP-018, ANR-07-MNP-Trafinlid]
  2. Swedish Research Council [2009-2318, 2007-8626]
  3. European Research Council (TreatPD) [242932]
  4. Michael J Fox Foundation
  5. National Institutes of Health/NINDS [NS060809-01, NS072359-01]
  6. Michael J. Fox Foundation for Parkinson's Research
  7. Parkinson's UK
  8. European Research Council (ERC) [242932] Funding Source: European Research Council (ERC)
  9. Parkinson's UK [G-1102] Funding Source: researchfish
  10. Agence Nationale de la Recherche (ANR) [ANR-07-JCJC-0090] Funding Source: Agence Nationale de la Recherche (ANR)

向作者/读者索取更多资源

Over the last two decades, significant strides has been made toward acquiring a better knowledge of both the etiology and pathogenesis of Parkinson's disease (PD). Experimental models are of paramount importance to obtain greater insights into the pathogenesis of the disease. Thus far, neurotoxin-based animal models have been the most popular tools employed to produce selective neuronal death in both in vitro and in vivo systems. These models have been commonly referred to as the pathogenic models. The current trend in modeling PD revolves around what can be called the disease gene-based models or etiologic models. The value of utilizing multiple models with a different mechanism of insult rests on the premise that dopamine-producing neurons die by stereotyped cascades that can be activated by a range of insults, from neurotoxins to downregulation and overexpression of disease-related genes. In this position article, we present the relevance of both pathogenic and etiologic models as well as the concept of clinically relevant designs that, we argue, should be utilized in the preclinical development phase of new neuroprotective therapies before embarking into clinical trials. (C) 2012 Movement Disorder Society

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据